Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cronos GroupFRA:7CI +0.14%86 Equity-to-Asset is 0.91 as of Jun. 2026, which is 1% below its 10-year median of 0.92. GuruFocus rates FRA:7CI with a GF Score™ of 86/100 and a GF Value™ of €3.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Cronos Group ranks better than 94.84% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cronos Group's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €927.6 Mil. Cronos Group's Total Assets for the quarter that ended in Jun. 2026 was €1,024.1 Mil.
Therefore, Cronos Group's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.91.
The historical rank and industry rank for Cronos Group's Equity-to-Asset or its related term are showing as below:
FRA:7CI'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36 Med: 0.92 Max: 0.98
Current: 0.91
During the past 12 years, the highest Equity to Asset Ratio of Cronos Group was 0.98. The lowest was 0.36. And the median was 0.92.
FRA:7CI's Equity-to-Asset is ranked better than 94.84% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs FRA:7CI: 0.91
Cronos Group (FRA:7CI) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cronos Group Equity-to-Asset Related Terms
Cronos Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cronos Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cronos Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cronos Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (FRA:7CI) has a Equity-to-Asset of 0.91 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cronos Group and its competitors. This is near median its historical median of 0.92. Over the past decade, Cronos Group's Equity-to-Asset has ranged from 0.36 to 0.98. According to the industry distribution chart, Cronos Group ranks #52 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Cronos Group's Equity-to-Asset too high?
Cronos Group's current Equity-to-Asset of 0.91 is near median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.98. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Cronos Group's value of 0.91 is 51.7% above this industry median. Based on the distribution chart, Cronos Group ranks #52 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #52 out of 1008 companies for Equity-to-Asset. This places Cronos Group in the top 5% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. Cronos Group's value of 0.91 is 51.7% above this benchmark. Historically, Cronos Group's own Equity-to-Asset has ranged from 0.36 to 0.98 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 0.60, Cronos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Equity-to-Asset of 0.91 is 51.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Equity-to-Asset is 0.91, which is near median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (FRA:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.15, compared to a current price of €2.77 — trading 12.2% below its estimated fair value. The current Equity-to-Asset is 0.91, which is near median its 10-year median of 0.92 and 51.7% above the Drug Manufacturers industry median of 0.60. Cronos Group's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cronos Group (FRA:7CI), the current Equity-to-Asset is 0.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (FRA:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.77 is trading 12.2% below its estimated GF Value™ of €3.15.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for FRA:7CI:
Equity-to-Asset: 0.91 (near median its 10-year median of 0.92)
GF Value™: €3.15 vs. price of €2.77 (12.2% below fair value)
Industry Position: 51.7% above the Drug Manufacturers median (#52 of 1008)
No single metric tells the full story. See the FRA:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for FRA:7CI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7CI has been successfully added to your 
